Soleno Therapeutics Inc SLNO
$53.01 $0.02 (0.04%) 1D
Last Updated: May 15, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
SLNO Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Soleno Therapeutics Inc is classified as halal.
HALAL
Report Source: undefined Quarter Report
Soleno Therapeutics Inc. Stock Analysis SLNO
United States Health Care Mid Cap Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is headquartered in Redwood City, California and currently employs 182 full-time employees. The company went IPO on 2014-10-23. Its first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, is a once-daily oral treatment for hyperphagia in adults and children four years of age and older with Prader-Willi syndrome (PWS). VYKAT XR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. The KATP channels play a central role in the regulation of a number of physiological processes which may otherwise be dysregulated, contributing to the pathophysiology of several diseases. In the context of the underlying genetic or structural defects in PWS, these pathophysiological processes may cumulatively contribute to increases in appetite and aggressive food seeking, lack of satiety, accumulation of excess body fat and the establishment and perpetuation of the obese state. PWS is a rare, complex genetic neurobehavioral/metabolic disorder.
Soleno Therapeutics Inc (SLNO) Chart
Financial Metrics & Statements of Soleno Therapeutics Inc (SLNO)
FAQ's for Soleno Therapeutics Inc (SLNO)
- As of August 2026, Soleno Therapeutics Inc SLNO is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Soleno Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Soleno Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Soleno Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Soleno Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Soleno Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Related Halal Stocks to Soleno Therapeutics Inc (SLNO)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
